← board
HUMAW
distress 9/10 · high distress / dilution risk$0.01-7%today-92% from 52w high
Lead: arteriovenous access for end-stage renal disease
Revenue
pre-revenue
Liquidity
$49M
Runway
0.5 yrs
Shares 1y
+40%
Price & events
-91.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-7.1%
1D
+0.0%
1W
-91.7%
1M
-91.7%
3M
—
6M
—
1Y
—
2Y
—
5Y
-91.1%
All
Overview
- Market Cap
- $2.02M
- Enterprise Value
- $-10.65M
- Volume
- 274
- 52 Week Range
- $0.01 – $0.12
- Total Shares
- 222.02M
- Float Shares
- 196.13M
- RVOL
- 0.32x
- Beta
- 2.52
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- October 28, 2024conferencedata presentationsecondaryPhase 3ATEV · Presentation of positive Phase 3 V007 results at ASN Kidney Week 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — arteriovenous access for end-stage renal disease
- none identified
Recent news
- 2026-07-20Humacyte, Inc. (HUMA) suffers a larger drop than the general market: Key insights - MSN
- 2026-07-18Humacyte, Inc. (HUMA) beats stock market upswing: What investors need to know - MSN
- 2026-07-14Humacyte appoints two nephrologists as commercial advisors By Investing.com - Investing.com South Africa
- 2026-07-14Humacyte appoints two nephrologists as commercial advisors By Investing.com - Investing.com Nigeria
- 2026-07-14Humacyte appoints two nephrologists as commercial advisors - Investing.com
- 2026-07-14Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - The Manila Times
- 2026-07-14Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - The Globe and Mail
- 2026-07-13Form 13D/A HUMACYTE For: 13 July By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.